Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA's FY 2023 User Fees Finally Revealed

Executive Summary

Several fees for prescription drug, generic drug, and biosimilar applications are set to increase, although some also will drop.

You may also be interested in...



US FDA Collects ‘Majority’ Of PDUFA Program Fees After Payment Plea

The revenue is expected to sustain the prescription drug user fee program moving forward after reserves were tapped at the start of fiscal year 2023.

Closing The Books On GDUFA II

Approval and submission data indicate steady trends aside from one outlier year.

With Increasing New Drug INDs Projected, How Much More Workload Can US FDA Handle?

Meanwhile, the biosimilars program is expecting essentially flat application numbers, but more manufacturing supplements and more development meetings, which likely is an indication of the sector’s flourishing in the US.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS147116

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel